This attached supplementary prospectus of Queensland Bauxite Ltd (ASX:QBL) has included some updated information on the original prospectus that was lodged with the ASIC on 27 September 2018.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce it has received a Notice of Intention to Grant a European patent covering the use of Progenza by the European Patent Office.
The Board of Queensland Bauxite Limited (ASX:QBL) is pleased to announce that its soon to be wholly owned subsidiary, Medcan Australia, has secured a Medical Cannabis Manufacture Licence under the ODC.
Anatara Lifesciences (ASX:ANR) is pleased to release its Annual Report, for the year ended 30th June 2018.
Melbourne based nasal respiratory company Rhinomed (ASX:RNO) (OTCMKTS:RHNMF) is pleased to advise investors it has signed a 12-year exclusive licensing agreement of its nasal platform technology with Columbia Care LLC, the largest and most experienced provider of cannabis-based products and services in the United States (U.S.).
Queensland Bauxite Ltd (ASX:QBL) Prospectus has been prepared for an offer of up to 170,000,000 new Shares at an issue price of $0.035 per Share to raise up to $5,950,000, with a minimum subscription of $1,995,000 together with one (1) free attaching Option for every two (2) Shares subscribed for and issued.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.4m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2018.
